Bicara Therapeutics Inc.
BCAX
$22.38
-$0.54-2.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.13M | 7.70M | 7.22M | 7.46M | 6.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.12M | 40.68M | 32.02M | 41.79M | 26.64M |
| Operating Income | -41.12M | -40.68M | -32.02M | -41.79M | -26.64M |
| Income Before Tax | -37.33M | -36.29M | -27.34M | -36.77M | -20.77M |
| Income Tax Expenses | 53.00K | 40.00K | 52.00K | 72.00K | 186.00K |
| Earnings from Continuing Operations | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.39M | -36.33M | -27.39M | -36.85M | -20.96M |
| EBIT | -41.12M | -40.68M | -32.02M | -41.79M | -26.64M |
| EBITDA | -41.08M | -40.65M | -32.00M | -41.77M | -26.62M |
| EPS Basic | -0.68 | -0.67 | -0.50 | -0.68 | -0.39 |
| Normalized Basic EPS | -0.42 | -0.42 | -0.31 | -0.42 | -0.24 |
| EPS Diluted | -0.68 | -0.67 | -0.50 | -0.68 | -0.39 |
| Normalized Diluted EPS | -0.42 | -0.42 | -0.31 | -0.42 | -0.24 |
| Average Basic Shares Outstanding | 55.14M | 54.56M | 54.54M | 54.46M | 54.42M |
| Average Diluted Shares Outstanding | 55.14M | 54.56M | 54.54M | 54.46M | 54.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |